SERF2-SNAP25 Antigen Combination for Autoantibody-Based AD Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) are inadequate in distinguishing between these conditions, leading to high misdiagnosis rates and difficulty in early detection due to similar clinical symptoms and imaging challenges.
Innovation Solution
A protein antigen combination comprising SERF2 and SNAP25, optionally with additional protein fragments, is used to detect autoantibodies that can accurately identify AD and differentiate it from FTD and DLB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (MMSE, imaging tests) are used for Alzheimer's disease, then diagnosis can be made based on clinical symptoms, but misdiagnosis rate is high and early detection is difficult
Solution Approach 1:
The patent introduces autoantibodies against SERF2 protein as an intermediary biomarker to detect Alzheimer's disease. These autoantibodies serve as a mediator between the disease pathology and detectable signal, enabling more accurate diagnosis than direct clinical assessment. The autoantibody detection acts as an intermediary step that translates complex disease states into measurable immunological responses.
Solution Approach 2:
The patent replaces mechanical/imaging-based diagnostic systems (MRI, CT, PET) with an immunological detection system. Instead of relying on physical imaging techniques that require expensive equipment and expert interpretation, the invention uses antibody-antigen binding reactions that can be detected through standardized immunoassays, substituting complex mechanical systems with simpler biochemical interactions.
2Measurement precision
If imaging examinations (MRI, SPECT/PET) are used to distinguish AD from DLB and FTD, then differentiation is possible, but physician experience requirements are high and complexity increases
Solution Approach 1:
The patent extracts the diagnostic function from complex imaging systems and concentrates it into a single biochemical marker - autoantibodies against SERF2. By taking out the essential diagnostic information and encoding it in the presence or absence of specific autoantibodies, the invention simplifies the diagnostic workflow while maintaining differentiation capability between AD, DLB, and FTD.
Solution Approach 2:
The patent changes the diagnostic parameter from structural/imaging features (brain atrophy patterns, perfusion changes) to immunological parameters (autoantibody presence, titers, and profiles). This parameter transformation converts a complex multi-dimensional imaging analysis into a more straightforward serological test that reduces dependency on physician expertise.
3Measurement precision
If cerebrospinal fluid biomarkers (beta amyloid, Tau proteins) are used to identify AD, then certain diagnostic information can be obtained, but patient risk increases due to invasive sampling
Solution Approach 1:
The patent uses serum autoantibodies as an intermediary marker that indirectly reflects central nervous system pathology. Instead of directly measuring proteins in the cerebrospinal fluid (which requires lumbar puncture), the invention detects autoantibodies in peripheral blood that are generated in response to brain pathology, providing a non-invasive window into CNS disease processes.
Solution Approach 2:
The patent creates a copy of the diagnostic information by detecting autoantibody responses in peripheral blood that mirror the pathological processes occurring in the central nervous system. The serum autoantibody profile serves as a copy or surrogate of the CSF biomarker profile, providing equivalent diagnostic value without the invasiveness of lumbar puncture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen combination effectively identifies AD and distinguishes it from FTD and DLB, providing accurate diagnostic tools with high specificity and sensitivity, reducing misdiagnosis rates.
Implementation Method 1
a protein antigen combination comprising SERF2 and SNAP25, optionally with additional protein fragments, is used to detect autoantibodies
Data Source
AI summary
A protein antigen combination containing SERF2 and applications thereof in the field of biological detection are disclosed. The antigen combination for detecting autoantibodies can distinguish Alzheimer's disease (AD) from frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and the antigen combination at least includes protein fragments of SERF2. The new protein antigen composition can not only effectively identify patients with AD, but also effectively distinguish AD from FTD and DLB, enabling accurate identification of AD. It is of great importance in terms of diagnostic applications and research.